Fondazione Ricerca Traslazionale
Clinical trials sponsored by Fondazione Ricerca Traslazionale, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Lung cancer trial: does adding a second drug boost survival? Results expected May 2027 (estimated)
- Blood test may reveal how lung cancer patients react to immunotherapy Results expected Sep 2027 (estimated)
-
Lung cancer trial: does adding a second drug boost survival?
Disease control OngoingThis Phase 2 trial compares the drug atezolizumab alone versus atezolizumab plus bevacizumab as a first treatment for people with advanced non-small-cell lung cancer that has a specific marker (PD-L1). About 206 patients are taking part. The main goal is to see if the combination…
Phase 2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy offers hope for lung cancer patients who stopped responding to initial treatment
Disease control OngoingThis study tests two drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) in people with advanced non-small-cell lung cancer whose disease worsened after initial chemo-immunotherapy. About 105 participants with a specific genetic marker (HLA-A2+) will receive one of…
Phase 2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC